Anti-Human CD25 Recombinant Antibody (Daclizumab) (CAT#: TAB-023)

Recombinant monoclonal antibody to Human CD25. Daclizumab (trade name daclizumab) is a therapeutic humanized monoclonal antibody. It is used to prevent rejection in organ transplantation, especially in kidney transplants. The drug is also under investigation for the treatment of multiple sclerosis. Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T cells.

Host: Mouse

Isotype: IgG1 - kappa

Applications: ELISA, Neut, IF, IP, FC, FuncS, MRI


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Tested Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
FC

Figure 1 Flow cytometric analysis of peripheral blood lymphocytes of a patient treated with daclizumab.

The dot plots in the first two columns are gated on lymphocytes, and those in the third and fourth columns are gated on CD3+cells. Following treatment, p55 is not detected by anti-CD25 nor by anti-humanized Tac (daclizumab) on CD3+ cells (first and second columns), but the CD3+ cells remain positive for HLA-DR (third column) and faintly positive for p55 using 7G7 (fourth column).

Przepiorka, D., Kernan, N. A., Ippoliti, C., Papadopoulos, E. B., Giralt, S., Khouri, I.,... & Champlin, R. (2000). Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood, 95(1), 83-89.

ELISA

Figure 2 Absolute numbers of cells after treatment with daclizumab.

Note the difference in scale of the y-axis between graphs. (A) Absolute number of lymphocytes (ALC) (solid line), CD3 + 56− (dashed line) and CD3 − 56+(dotted line) cells after treatment with daclizumab. (B) Absolute number of CD3 + 56− cells (solid line), CD3+DR+ cells (dashed line), CD3 + 7G7+ cells (dotted line), and CD3 + 25+ cells (thin line) after treatment with daclizumab.

Przepiorka, D., Kernan, N. A., Ippoliti, C., Papadopoulos, E. B., Giralt, S., Khouri, I.,... & Champlin, R. (2000). Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood, 95(1), 83-89.

MRI

Figure 3 Change in CEL on brain MRI during daclizumab trial: individual patients (A) and cumulative lesion analysis (B).

(A) Evolution of new CEL on brain MRI during daclizumab trial. All 11 patients are presented. Group average for each time point is calculated from data on 10 MS patients who received 1 mg/kg daclizumab dosing. (B) Cumulative lesion analysis of new and total CEL during daclizumab trial. Number of new (and total) CEL per each month were added together for 10 MS patients and plotted as a cumulative lesion analysis. There is proportional monthly accumulation of CEL in the whole cohort (as evident from the linear relationship), and daclizumab add-on leads to gradual decrease in cumulative CEL (change in slope) that becomes evident after 1.5–2 months of therapy.

Bielekova, B., Richert, N., Howard, T., Blevins, G., Markovic-Plese, S., McCartin, J.,... & Martin, R. (2004). Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β. Proceedings of the National Academy of Sciences, 101(23), 8705-8708.

ELISA

Figure 4 Daclizumab treatment decreases CSF levels of CXCL13 and intrathecal production of IgG.

(A) CSF CXCL13 concentration was measured by ELISA. (B) IgG index as measured by NIH clinical laboratory. Raw data for individual patients measured before (Baseline) and 6.5 months after initiation of daclizumab therapy (Dac Th) are depicted as gray dot and line blots and group data are depicted as box plots with mean highlighted as red and median as black horizontal line.

Perry, J. S., Han, S., Xu, Q., Herman, M. L., Kennedy, L. B., Csako, G., & Bielekova, B. (2012). Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Science translational medicine, 4(145), 145ra106-145ra106.

FuncS

Figure 5 Enhanced intermediate IL-2/IL-15 signaling in daclizumab-treated patients promotes differentiation of ILCs toward functional NK cells (A) Representative pSTAT5 levels of untreated or daclizumab (Dac Th) treated MS patients.

Purified ILCs were stimulated with IL-2 (100IU/ml), IL-7 (10ng/ml), IL-15 (10ng/ml) or no cytokine for 10 minutes (optimal concentrations determined in pilot experiments). ILCs were then immediately fixed and stained for phosphorylated Stat5 production. (B) Group signaling data analogous to (A). (C) Purified c-kit + ILCs cells were cultured for 7 days in media supplemented with SCF and Flt3L (both 10ng/ml) and in the presence of IL-2 (100IU/ml), IL-7 (10ng/ml), IL-15 (10ng/ ml) or no cytokine control. At day 7, cultured cells were stained and analyzed by FACS for the presence of CD56 + NK cells (compared to ex vivo PBMCs of daclizumab-treated MS patients with significant expansion of CD56 bright NK cells). (C) Raw data from a representative experiment and (D) represents group data of the number of CD56 dim NK and CD56 bright NK cells per 1,000 beads. (E) Purified c-kit + ILCs were cultured as in panel C. At day 7, cultured cells were FACS stained for functional NK markers (Perforin, Granzyme A and B; compared to ex vivo PBMC of daclizumab-treated MS patients with significant expansion of CD56 bright NK cells). FACS plots are representative of 4 replications. (F) Also on day 7, cultured cells were incubated for ~16hr with target GFP-tagged K562 cells at a 1:1 effector to target ratio (or K562 cell only control wells). K562 killing was then.

Perry, J. S., Han, S., Xu, Q., Herman, M. L., Kennedy, L. B., Csako, G., & Bielekova, B. (2012). Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Science translational medicine, 4(145), 145ra106-145ra106.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Mouse
  • Derivation
  • Humanized (from mouse)
  • Type
  • IgG1 - kappa
  • Specificity
  • Tested positive against native human antigen
  • Species Reactivity
  • Human
  • Applications
  • ELISA, Neut, IF, IP, FC, FuncS, MRI
  • Trade name
  • daclizumab
  • CAS
  • 152923-56-3
  • Generic Name
  • Daclizumab
  • Biological Half-Life
  • 20 days (11–38 days)
  • ATC Code
  • L04AC01
  • DrugBank
  • DB00111
  • UNII
  • CUJ2MVI71Y
  • ChEMBL
  • CHEMBL1201605
  • MW
  • 142,612.1 g/mol
  • Related Disease
  • Multiple sclerosis (MS)

Product Property

  • Purity
  • >97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
  • Storage
  • Store at -20°C for long-term storage. Store at 2-8°C for up to one month. Avoid freeze/thaw cycles.

Applications

  • Application Notes
  • The IL2RA antibody has been reported in applications of ELISA, Neut, IF, IP, FC, FuncS, MRI.

Target

  • Alternative Names
  • Daclizumab;daclizumab;152923-56-3;dacliximab;Ro 24-7375;anti-TAC;DB00111IL2RA;interleukin 2 receptor, alpha;IL2R;interleukin-2 receptor subunit alpha;CD25;p55;IL2-RA;IL-2-RA;TAC antigen;IL-2R subunit alpha;IL-2 receptor subunit alpha;TCGFR;IDDM10;

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Daclizumab"

Afuco™ Anti-IL2RA ADCC Recombinant Antibody (Daclizumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Human CD25. Daclizumab (trade name daclizumab) is a therapeutic humanized monoclonal antibody. It is used to prevent rejection in organ transplantation, especially in kidney transplants. The drug is also under investigation for the treatment of multiple sclerosis. Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T cells.

See other products for "IL2RA"

Recombinant Antibody

CAT Product Name Application Type
MOB-1094z Mouse Anti-IL2RA Recombinant Antibody (clone 18C9) WB, ELISA, IF, IHC, FuncS Mouse IgG1, κ
PABZ-082 Human Anti-IL2RA Recombinant Antibody (clone SDZ CHI621) Block Chimeric (mouse/human) IgG
MOB-0351MZ Recombinant Mouse Anti-Human IL2RA Antibody (clone BCT-2) ELISA Mouse antibody
FAMAB-0197CQ Mouse Anti-IL2RA Recombinant Antibody (clone 2C8) ELISA, WB, FC Mouse IgG1, κ
FAMAB-0198CQ Human Anti-IL2RA Recombinant Antibody (clone 4C1) ELISA, WB, FC Chimeric (mouse/human) IgG1, κ

Intrabody

CAT Product Name Application Type
IAB-B073(A) Recombinant Anti-human IL2RA Intrabody [(D-Arg)9] IF, ELISA, FuncS scFv-(D-Arg)9
IAB-B073(G) Recombinant Anti-human IL2RA Intrabody [+36 GFP] IF, FC, WB, FuncS scFv-(+36GFP)
IAB-B073(T) Recombinant Anti-human IL2RA Intrabody [Tat] WB, CO-IP, FuncS scFv-Tat

Chimeric Antibody

CAT Product Name Application Type
TAB-004 Anti-Human CD25 Recombinant Antibody (Basiliximab) IF, IP, Neut, FuncS, ELISA, FC, ICC IgG1 - kappa
PABX-030 Recombinant Human Anti-CD25 Antibody (SDZCHII621) Neut, FuncS IgG
PABX-030-F (E) Recombinant Mouse Anti-CD25 Antibody Fab Fragment (SDZCHII621) Neut, FuncS Fab

Mouse Antibody

CAT Product Name Application Type
TAB-155 Anti-Human CD25 Recombinant Antibody (Inolimomab) IP, IF, FuncS, FC, Neut, ELISA, ICC IgG1 - kappa
TAB-641LC Anti-human IL2RA Recombinant Antibody (Inolimomab) (TAB-641LC) ELISA
TAB-641LC-S(P) Anti-human IL2RA scFv Fragment (Inolimomab) ELISA
TAB-641LC-F(E) Anti-human IL2RA Fab Fragment (Inolimomab) ELISA
PABX-029-S (P) Recombinant Human Anti-CD25 Antibody scFv Fragment (Daclizumab) WB, ELISA, FuncS scFv

Immunotoxin

CAT Product Name Application Type
AGTO-L027D anti-IL2RA immunotoxin RFT5 (scFv)-DT Cytotoxicity assay, Functional assay
AGTO-L027R anti-IL2RA immunotoxin RFT5 (scFv)-RTA Cytotoxicity assay, Functional assay
AGTO-L078E IL2-PE immunotoxin Cytotoxicity assay, Functional assay
AGTO-L078D IL2-DT immunotoxin Cytotoxicity assay, Functional assay
AGTO-L078R IL2-RTA immunotoxin Cytotoxicity assay, Functional assay

Fab Fragment Antibody

CAT Product Name Application Type
PFBZ-020 Human Anti-IL2RA Recombinant Antibody (clone CHI621); Fab Fragment Block Chimeric (mouse/human) Fab
PFBZ-082 Human Anti-IL2RA Recombinant Antibody (clone SDZ CHI621); Fab Fragment Block Chimeric (mouse/human) Fab
FAMAB-0197CQ-F(E) Mouse Anti-IL2RA Recombinant Antibody (clone 2C8); Fab Fragment ELISA, WB, FC Mouse Fab
HPAB-2113-FY-F(E) Mouse Anti-IL2RA Recombinant Antibody (clone MAK179); Fab Fragment Inhib Mouse Fab
HPAB-1536WJ-F(E) Rat Anti-IL2RA Recombinant Antibody; Fab Fragment (clone YTH 906.9.21) ELISA, WB Rat Fab

scFv Fragment Antibody

CAT Product Name Application Type
PSBZ-082 Mouse Anti-IL2RA Recombinant Antibody (clone SDZ CHI621); scFv Fragment Block Mouse scFv
PSBL-608 Mouse Anti-IL2RA Recombinant Antibody (clone RTF5); scFv Fragment WB, FuncS Mouse scFv
HPAB-0559-WJ-S(P) Human Anti-IL2RA Recombinant Antibody; scFv Fragment (HPAB-0559-WJ-S(P)) ELISA, FC Human scFv
HPAB-0560-WJ-S(P) Human Anti-IL2RA Recombinant Antibody; scFv Fragment (HPAB-0560-WJ-S(P)) ELISA, FC Human scFv
HPAB-0561-WJ-S(P) Human Anti-IL2RA Recombinant Antibody; scFv Fragment (HPAB-0561-WJ-S(P)) ELISA, FC Human scFv

Human Antibody

CAT Product Name Application Type
TAB-642LC Human Anti-IL2RA Recombinant Antibody (TAB-642LC) ELISA, FC, Inhib Human IgG1, κ
TAB-642LC-F(E) Human Anti-IL2RA Recombinant Antibody; Fab Fragment (TAB-642LC-F(E)) ELISA, FC Human Fab
TAB-643LC-F(E) Human Anti-IL2RA Recombinant Antibody; Fab Fragment (TAB-643LC-F(E)) ELISA, FC Human Fab
TAB-644LC-F(E) Human Anti-IL2RA Recombinant Antibody; Fab Fragment (TAB-644LC-F(E)) ELISA, FC Human Fab
TAB-645LC-F(E) Human Anti-IL2RA Recombinant Antibody; Fab Fragment (TAB-645LC-F(E)) ELISA, FC Human Fab

Humanized Antibody

CAT Product Name Application Type
TAB-646LC-S(P) Anti-human IL2RA scFv Fragment (48M54S) ELISA, FC Humanized antibody
TAB-647LC-S(P) Anti-human IL2RA scFv Fragment (48M51L) ELISA, FC Humanized antibody
TAB-648LC-S(P) Anti-human IL2RA scFv Fragment (48V54S) ELISA, FC Humanized antibody
TAB-649LC-S(P) Anti-human IL2RA scFv Fragment (Dmab) FC Humanized antibody
TAB-650LC-S(P) Human Anti-IL2RA Recombinant Antibody; scFv Fragment (TAB-650LC-S(P)) ELISA Humanized scFv

Neutralizing Antibody

CAT Product Name Application Type
NEUT-1344CQ Mouse Anti-IL2RA Recombinant Antibody (clone B-B10) FC, Neut, WB, IF Mouse IgG1, κ
NEUT-1345CQ Mouse Anti-IL2RA Recombinant Antibody (clone CBL017) Neut, WB, IHC Mouse IgG1
NEUT-1346CQ Mouse Anti-IL2RA Recombinant Antibody (clone CBL242) ELISA, FC, Neut Mouse IgG1, κ
NEUT-1348CQ Mouse Anti-IL2RA Recombinant Antibody (clone CBL726) WB, IHC, ICC, Neut Mouse IgG1
NEUT-1349CQ Mouse Anti-IL2RA Recombinant Antibody (clone 1X27) IHC, Neut, WB Mouse IgG1

Blocking Antibody

CAT Product Name Application Type
NEUT-1350CQ Mouse Anti-IL2RA Recombinant Antibody (clone 2R12) Block, FC, ICC, IF, IHC, IP, WB Mouse IgG1
NEUT-1356CQ Rat Anti-Il2ra Recombinant Antibody (clone PC61) FC, IP, IHC, Block, Depletion Rat IgG1, λ
NEUT-1357CQ Rat Anti-Il2ra Recombinant Antibody (clone 3C7) FC, IP, Inhib Rat IgG2b, κ
NEUT-1358CQ Rat Anti-Il2ra Recombinant Antibody (clone mAb0817) Block, Depletion Rat IgG1
NEUT-1359CQ Rat Anti-Il2ra Recombinant Antibody (clone mAb0845) Block, FC, IHC-Fr, IP Rat IgG1

Rabbit Monoclonal Antibody

CAT Product Name Application Type
MOR-1808 Rabbit Anti-IL2RA Recombinant Antibody (clone DS1808AB) IHC, ICC, IP Rabbit IgG

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-004 Afuco™ Anti-IL2RA ADCC Recombinant Antibody (Basiliximab), ADCC Enhanced IF, IP, Neut, FuncS, ELISA, FC ADCC enhanced antibody
AFC-TAB-023 Afuco™ Anti-IL2RA ADCC Recombinant Antibody (Daclizumab), ADCC Enhanced ELISA, Neut, IF, IP, FC, FuncS ADCC enhanced antibody
AFC-TAB-155 Afuco™ Anti-IL2RA ADCC Recombinant Antibody (Inolimomab), ADCC Enhanced IP, IF, FuncS, FC, Neut, ELISA ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-023. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

* Abbreviations
Send Inquiry
© 2023 Creative BioLabs. All Rights Reserved
  • 0
  • 0
Cart